Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.82 |
| ▸ | CYP2J2 | P51589 | 6/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108219 | 0.92 | EPHX2 (0.79) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL13873613 | 0.90 | EPHX2 (1.00) | EPHX2CYP2C9CYP2J2LIPE | |
| SCHEMBL4097087 | 0.88 | EPHX2 (0.64) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL4107231 | 0.88 | EPHX2 (0.72) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL4103790 | 0.86 | EPHX2 (0.84) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL4114888 | 0.86 | EPHX2 (0.62) | EPHX2CYP2C9CYP2J2ALDH1A1 | |
| SCHEMBL4111780 | 0.85 | EPHX2 (1.00) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL4100317 | 0.84 | EPHX2 (0.65) | EPHX2CYP2C9CYP2J2ALDH1A1TSHR | |
| SCHEMBL13874793 | 0.84 | EPHX2 (0.62) | EPHX2CYP2C9CYP2J2ALDH1A1TSHR | |
| SCHEMBL13873467 | 0.83 | EPHX2 (0.64) | EPHX2CYP2C9CYP2J2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 477/4885CYP2J2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.